Biogen inc. (BIIB)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07
Cash flows from operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

5,888

4,474

2,670

3,695

3,593

2,941

1,862

1,380

1,266

898

977

790

579

Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation, amortization and impairments

680

1,016

1,081

682

600

688

531

365

358

355

427

462

380

Acquired in-process research and development

0

112

120

0

0

-

-

-

-

271

-

25

136

Share-based compensation

182

157

128

154

161

155

136

118

113

167

160

146

123

Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings

63

12

-62

-14

-30

-

-

-

-

-

-

-

-

Loss on divestiture of Hillerød, Denmark manufacturing operations

-55

0

0

-

-

-

-

-

-

-

-

-

-

Fair value adjustment of contingent consideration

-

-

-

-

-

-

-

-

-

0

-

-

-

Excess tax benefit from share-based compensation

-

-

-

-

-

-

-

-

-

13

3

27

-69

Deferred income taxes

67

108

91

-175

-145

-308

-245

-116

153

-81

-137

-139

-81

Write-down of inventory to net realizeable value

-

-

-

-

-

-

-

-

-

11

16

29

21

Impairment of marketable securities, investments and other assets

-

-

-

-

-

-

-

-

-

-

16

61

24

Realized (gain) loss on sale of marketable securities and strategic investments

-

-

-

-

-

-

-

-

-

-

23

-1

-16

Non-cash interest (income) expense, foreign exchange remeasurement loss (gain), net and other

-

-

-

-

-

-

-

-

-

-

-7

-4

1

Other

-69

69

-162

-89

-129

50

27

-28

-20

-10

-

-

-

Changes in operating assets and liabilities, net:
Cash received upon termination of interest rate swap

-

-

-

-

-

-

-

-

-

-

-

53

0

(Gain) loss on disposal of property, plant and equipment, net

-

-

-

-

-

-

-

-

-

-

-

9

0

Accounts receivable

-68

205

435

241

-29

512

126

-3

73

99

100

57

-70

Due from unconsolidated joint business

-

-

-

-

-

-

-

-

-

28

-13

40

2

Inventory

19

52

94

165

174

185

243

140

59

4

42

54

-83

Other assets

-

-

-

-59

127

108

160

27

43

12

-22

-3

0

Accrued expenses and other current liabilities

240

465

-227

622

199

244

284

273

33

130

-48

146

30

Income tax assets and liabilities

16

321

1,303

-232

-429

40

156

-

-

-

-

-

-

Other changes in operating assets and liabilities, net

63

-5

232

-13

31

30

-15

39

6

-

-

-

-

Other liabilities

-43

-135

-79

69

83

68

161

34

-36

17

-194

176

41

Net cash flows provided by operating activities

7,078

6,187

4,551

4,587

3,919

2,942

2,345

1,879

1,727

1,624

1,074

1,562

1,018

Cash flows from investing activities:
Proceeds from sales and maturities of marketable securities

6,007

9,173

5,565

7,378

4,063

2,718

5,190

2,749

2,276

2,668

3,319

2,941

3,154

Purchases of marketable securities

5,252

7,694

5,355

7,913

6,864

3,583

3,278

3,334

3,696

1,988

3,548

3,163

2,945

Contingent consideration paid related to Fumapharm AG acquisition

300

1,500

1,200

1,200

850

375

15

0

-

-

-

-

-

Acquisitions of businesses and variable interest entities, net of cash acquired

-

-

-

-

-

-

-

-

-

157

-

-

-

Purchases of property, plant and equipment

514

770

867

616

643

287

246

254

208

173

165

275

284

Payments to Acquire Businesses, Net of Cash Acquired

744

0

0

-

198

0

0

72

5

-

-

25

95

Proceeds from the sale of strategic investments and long-lived assets

-

-

-

-

-

-

-

-

-

0

-

-

-

Proceeds from Sale of Property, Plant, and Equipment

923

0

0

-

-

-

-

-

-

-

-

-

16

Acquired in-process research and development

0

112

120

0

0

-

-

-

-

-

-

-

-

Acquisitions of intangible assets

155

3

975

111

15

28

3,262

0

0

0

-

-

-

Payments to Acquire Other Investments

0

462

0

0

-

-

-

-

-

4

44

20

23

Payments to Acquire Equity Method Investments

0

676

0

0

-

-

-

-

-

-

-

-

-

Proceeds from sales of strategic investments

479

0

0

-

-

-

-

-

-

-

-

-

-

Other

-27

-0

11

22

44

-12

-7

38

16

-

-

-

-

Proceeds from the sale of strategic investments

-

-

-

-

-

-

-

-

-

-

13

-

99

Collateral received under securities lending

-

-

-

-

-

-

-

-

-

-

29

178

-208

Net cash flows provided by investing activities

470

-2,046

-2,963

-2,484

-4,553

-1,543

-1,604

-950

-1,650

345

-395

-365

-286

Cash flows from financing activities:
Purchases of treasury stock

5,868

4,352

1,365

1,000

5,000

886

400

984

497

2,077

751

738

2,991

Payments related to issuance of stock for share-based compensation arrangements, net

-

-

-

8

70

-

-

-

-

-

-

-

-

Repayments of Long-term Debt

-

-

-

-

-

-

-

-

-

-

-

-

6

Payments to Noncontrolling Interests

-4

36

134

0

56

-

-

-

-

23

-4

-2

-1

Proceeds from issuance of stock for share-based compensation arrangements

-

-

-

-

-

54

66

67

314

183

47

178

489

Proceeds from borrowings

-

-

-

-

5,930

0

0

-

-

-

-

986

1,512

Change in cash overdraft

-

-

-

-

-

-

-

-

-

-

12

-0

-5

Acquisition of noncontrolling interests

-

-

-

-

-

-

-

-

148

0

-

-

-

Repayments of borrowings

0

3

560

2

2

2

452

2

11

18

10

1,512

12

Net cash contribution to Bioverativ, Inc.

0

0

302

0

0

-

-

-

-

-

-

-

-

Excess tax benefit from share-based compensation

-

-

-

-

-

96

73

54

50

13

3

27

69

Contingent consideration payments

0

58

3

38

13

20

-

-

-

-

-

-

-

Cash payments for contingent consideration

-

-

-

-

-

-

-

-

-

0

-

-

-

Net proceeds from financing arrangement for the sale of the San Diego facility

-

-

-

-

-

-

-

-

-

126

-

-

-

Other

3

-21

-13

-2

-5

2

-4

-12

-27

10

-

-

-

Obligation under securities lending

-

-

-

-

-

-

-

-

-

-

29

178

-208

Net cash flows used in financing activities

-5,860

-4,472

-2,380

-1,052

783

-755

-716

-877

-319

-1,784

-724

-1,234

-733

Net increase (decrease) in cash and cash equivalents

1,688

-330

-792

1,049

148

643

23

52

-242

185

-44

-38

-1

Effect of exchange rate changes on cash and cash equivalents

0

-18

39

-31

-45

-40

8

4

-2

-7

3

0

-0

Interest

-

-

-

-

-

-

-

-

-

-

-

-

35

Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

251

Conversion of subordinated notes to common and treasury stock

-

-

-

-

-

-

-

-

-

-

-

-

38